e-Drug3D

2184

ZIFTOMENIB

INN
ZIFTOMENIB

cas 2134675-36-6

CLASS

ANTINEOPLASTIC
MENIN INHIBITOR
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

ROUTE (list)

ORAL

ATC code

PK parameters

F 12.9 PERCENT
Tmax 4.1 HOUR
VD 30100 LITER
Cl 101.2 LITER / HOUR
PPB 99 PERCENT
t1/2 93.6 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET MENIN

PDB
8VA5 (MENIN MUTANT - T349M IN COMPLEX WITH ZIFTOMENIB (KO-539))

Ligand code = K5O (link to the list of PDB complexes)

Download experimental 3D coordinates of K5O with added hydrogens

DrugCentral

Download SDF file

1H-Indole-2-carbonitrile, 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-1-[(2S)-2-[4-(methylsulfonyl)-1-piperazinyl]propyl]-

Formula:
C33H42F3N9O2S2

Calculated chemical properties:

MW 717.90
NB_atoms 49
XLogP 5.01
PSA 112.585
NB_HD 2
NB_HA 11
fsp3 0.55
Lipinski(0=no;1=yes) 0

FDA
NDA 220305 (label) INN (ZIFTOMENIB) KOMZIFTI (KURA) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY